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Cases of severe acute respiratory syndrome (SARS)
were investigated for SARS coronavirus (SARS-CoV)
through RNAtests, serologic response, and viral culture. Of
537 specimens from patients in whom SARS was clinically
diagnosed, 332 (60%) had SARS-CoV RNA in one or more
clinical specimens, compared with 1 (0.3%) of 332 samples
from controls. Of 417 patients with clinical SARS from
whom paired serum samples were available, 92% had an
antibody response. Rates of viral RNA positivity increased
progressively and peaked at day 11 after onset of illness.
Although viral RNA remained detectable in respiratory
secretions and stool and urine specimens for >30 days in
some patients, virus could not be cultured after week 3 of
illness. Nasopharyngeal aspirates, throat swabs, or sputum
samples were the most useful clinical specimens in the first
5 days of illness, but later in the illness viral RNA could be
detected more readily in stool specimens. 
I
n early 2003, severe acute respiratory syndrome (SARS)
was recognized as a newly emerging pneumonic disease
(1–3). A proportion of patients have watery diarrhea, usu-
ally at a later stage of the illness, suggesting that the infec-
tion may not be confined to the respiratory tract (4). A
novel coronavirus, designated as SARS coronavirus
(SARS-CoV), was implicated as the causative agent (5–7),
and the respiratory disease has been reproduced in a non-
primate animal model (8). Hong Kong was one of the
regions most affected, with >1,700 patients. Specific labo-
ratory tests to detect viral RNAand antibody responses (5)
were used to establish a cause in patients suspected to have
SARS. Although virologic results for small cohorts of
patients have been reported (4,5,9), analysis of results of
these first-generation tests in routine clinical practice has
not been published previously. We report the correlation of
results of reverse transcriptase polymerase chain reaction
(RT-PCR) and immunofluorescent serologic testing for
SARS-CoV in 1,048 cases investigated for SARS in the
first 5 weeks after the first-generation diagnostic tests
became available in Hong Kong. 
Methods 
Patients 
In the weeks after the first-generation viral diagnostic
tests became available in Hong Kong, SARS-CoV diagno-
sis was carried out in three laboratories, one of which was
the Department of Microbiology of Queen Mary Hospital
(QMH). Results from specimens investigated at QMH lab-
oratory from April 1 through May 3, 2003, and subsequent
follow-up specimens are included in this analysis. Clinical
specimens used for viral RNAdetection included nasopha-
ryngeal aspirates, throat and nose swabs, saliva, sputum,
endotracheal aspirates, feces, and urine. Nasopharyngeal
aspirates were collected into a mucus trap, and residual
secretions in the catheter were sucked into the trap by aspi-
rating 2 mL of virus transport medium. Swabs were col-
lected into 2 mLof virus transport medium containing van-
comycin (final concentration 100 µg/mL), amikacin
(30 µg/mL), and nystatin (40 U/mL). Urine and feces were
collected into specimen containers and submitted directly
to the laboratory without the addition of transport medium. 
The case definition has been previously described
(5,10). Patients were categorized on a clinical basis as
“clinical SARS,” “suspected SARS,” and “not SARS” by
the attending clinicians, depending on the response to
antimicrobial therapy for bacterial pathogens (e.g.,
tazocin 2.25–4.5 g intravenously 6–8 h/d, or azithromycin
500 mg/d for 7–10/d), the clinical and radiologic evolu-
tion of the illness, history of contact with other patients
with SARS, and an alternative diagnosis that fully
explained the clinical findings. 
Fecal, throat swab, and serum specimens from controls
were obtained for comparison. Fecal specimens from
patients with diarrhea were anonymously tested for SARS-
CoV RNA. Throat swab specimens were collected after
informed consent from patients attending primary care
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CoV RNA. Blood donor sera left over from screening for
bloodborne viruses were tested anonymously for antibod-
ies to SARS-CoV. 
Viral RNA Detection
RNAextraction was performed by using QIAamp Viral
RNAkit reagents (Qiagen, Hilden, Germany) according to
the manufacturer’s instructions. The RT-PCR primers and
conditions have been described (5,11). Since these primers
gave occasional false-positive reactions with stool speci-
mens, all PCR-positive stool specimens were retested by
the LightCycler PCR (Roche Diagnostics GmbH,
Mannheim, Germany) for confirmation using the same two
sets of primers, with the melting curve analysis being used
to provide additional confirmation of reaction specificity
(9). A plasmid vector pCRII-TOPO (Invitrogen, San
Diego, CA) containing the RNA-dependent RNA poly-
merase-encoding sequence of the virus was used as the
reference standard. A series of five log10 dilutions corre-
sponding to 1 x 101 to 1 x 106 copies per reaction of refer-
ence standard was run in parallel with the test samples. 
Virus Isolation
Specimens resuspended in virus transport medium
(200 µL) were used for infecting fetal rhesus monkey kid-
ney (FRhK-4) cell monolayers in culture tubes.
Approximately 1 g of feces samples was resuspended in
10 mL virus transport medium and centrifuged, and the
supernatant was spread onto cells. The respiratory sam-
ples were already diluted in virus transport medium and
spread onto the cell monolayer. After incubation at 37°C
for 1 h, the cells were fed with 1 mL of minimum essen-
tial medium with 1% fetal calf serum (GibcoBRL, Grand
Island, NY) and incubated at 37°C. The cultures were
examined for cytopathic effect (CPE) each day for 14
days. At the end of the incubation period or when CPE
appeared, the cells were spotted on Teflon-coated slides,
fixed with ice-cold acetone, and stained for SARS-CoV
antigen by using a convalescent-phase human serum. The
identification of the isolate was confirmed by RT-PCR.
Serologic Testing
Coronavirus immunoglobulin G serologic testing was
performed by indirect immunofluorescence. Batches of
SARS-CoV–infected Vero cell smears were prepared and
fixed in ice-cold acetone for 10 minutes. The cells were
adjusted to be 60% to 70% SARS-CoV infected, as judged
by immunofluorescent staining with a control positive
human convalescent-phase serum. The fixed smears were
stored at –70°C until use. Serum samples were screened at
a dilution of 1:10 on infected and uninfected control cells.
After 30 minutes of incubation, the cells were washed
twice in phosphate-buffered saline (PBS) for 5 minutes
each, and then goat anti-human fluorescein isothiocyanate
conjugate (INOVA Diagnostics, Inc., San Diego, CA) was
added, and the cells were incubated for 30 minutes at
37°C. The cells were washed again as described and exam-
ined with an immunofluorescent microscope. Serum sam-
ples positive at a screening dilution of 1:10 were titrated
with serial twofold dilutions in parallel with the respective
acute-phase serum specimen from the same patient. Apos-
itive control serum was tested with each batch of cells. 
Biosafety
Virus isolation or preparing cell smears for serologic
testing was done in a biosafety level (BSL) 3 laboratory.
Routine handling of clinical specimens for RNAextraction
and serologic testing by immunofluorescence were done in
a BSL-2 laboratory. Basic laboratory practice was rein-
forced by educating staff and closely supervising work
practices. Serum specimens for antibody testing were heat
inactivated at 56°C for 30 minutes before testing.
Results
The sensitivity and specificity of the RT-PCR and the
real time LightCycler assays have been reported (9,11,12).
Atotal of 3,611 respiratory, fecal, and urine specimens and
1,699 serum samples were tested for SARS-CoV RNAand
antibody, respectively, from 1,048 patients for whom an
initial clinical suspicion of SARS was considered. The lab-
oratory results were retrospectively correlated with the
clinical diagnoses of these patients. Clinically, 590 of these
patients were considered to have clinical SARS, 79 to have
suspected SARS, and 379 not to have SARS. The third
group included patients hospitalized with febrile respirato-
ry illnesses, many with radiologic changes, in whom
SARS had been initially considered in the differential
diagnosis. 
Overall, 948 (91%) of the patients had one or more
specimens tested for SARS-CoV RNA by RT-PCR, and
454 (43%) had acute- and convalescent-phase serum sam-
ples available for serologic analysis, with a convalescent-
phase serum taken at least 21 days after onset of illness.
While specimens for RT-PCR were available from similar
proportions (89%–91%) of patients in each clinical catego-
ry, paired sera were more frequently available from
patients clinically categorized as having SARS (417 [71%]
from 590) than from patients in the not SARS category (25
[7%] from 379) (Table 1). 
Of the patients clinically diagnosed as having SARS,
322 (60%) of 537 patients had evidence of SARS-CoV
RNA in clinical specimens. In contrast, 2 (0.6%) of 341 of
those clinically diagnosed as the “not SARS” category had
RT-PCR evidence of SARS-CoV infection (Table 1). To
assess the extent of circulation of SARS-CoV in the gener-
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gation of diarrheal illnesses from patients thought not to
have SARS) and 148 nose and throat swabs (from patients
visiting a general practice for nonrespiratory illnesses)
were tested for viral RNA by RT-PCR. None of 148 con-
trol throat swab specimens and 1 of 184 control stool spec-
imens had evidence of detectable SARS-CoV RNA.
Of 417 patients with clinical SARS for whom paired
sera were available, 383 (92%) had a >4-fold rise in anti-
body titer to SARS-CoV. None of 45 controls had serocon-
version to SARS-CoV. Two (8%) of 25 patients clinically
diagnosed as the “not SARS” category seroconverted
(Table 2), but a further 47 convalescent-phase sera from
patients in this group failed to show any more seropositive
patients (data not shown). Neither of these two patients
had a history of contact with other patients with SARS.
However, one had a left mid-zone consolidation confirmed
by high-resolution computed tomography scan and had a
discharge diagnosis of pneumonia of unknown cause. The
other had a mild febrile illness of unknown cause without
radiologic evidence of consolidation. None of 200 blood
donor serum samples collected in Hong Kong during
March 2003 and 2,200 additional serum samples collected
in May 2003 had evidence of antibody to SARS. 
The profile of SARS-CoV RNA detection in the 386
patients with serologically confirmed SARS-CoV infec-
tion was analyzed (Figure). Viral RNA was detectable in
the respiratory tract of a proportion (11%–42%) of patients
within the first 4 days of illness but was not detectable in
stool or urine specimens until days 5 and 7 of the illness,
respectively. The proportion of respiratory and stool spec-
imens positive for viral RNA progressively increased and
then peaked at approximately day 11 of the illness. While
the nasopharyngeal aspirates and throat and nose swabs
were the most productive specimens in the first 4 days of
disease, stool samples were more useful after the 5th day
of illness. Although the rate of detection in clinical speci-
mens gradually decreased from day 16 onward, viral RNA
could still be detected after 30 days of illness in samples
from the nasopharynx, feces, and urine in a small propor-
tion of patients (Figure). Smaller numbers of saliva, endo-
tracheal aspirate, and sputum specimens were available for
testing (Table 3). 
Since confirmation of a laboratory diagnosis of SARS
within the first 5 days of illness is the greatest clinical
need, we studied the diagnostic yield from different speci-
mens in patients with serologically confirmed SARS-CoV
infection during this period (Table 4). Sputum appeared to
be a good clinical specimen in the early stage of the dis-
ease, although the number of specimens tested was small.
Nasopharyngeal aspirates and throat and nose swabs
appear to be of comparable sensitivity (30% and 28%,
respectively), while stool specimens are less useful speci-
mens in the first 5 days of illness (sensitivity 20%). Saliva
and endotracheal aspirates are alternative specimens
(Table 3), but we could not assess their usefulness because
of the lack of specimens collected in the early stage of the
illness. In patients whose first specimen tested negative, 25
had a second specimen (of any type) collected within the
first 5 days of illness. Three of these 25 were positive; the
additional diagnostic yield from a second specimen was
approximately 12% (data not shown).  
Virus was isolated retrospectively from stored clinical
specimens that were RT-PCR positive for viral RNA(Table
5). Virus was more readily isolated from the respiratory
tract than from stool specimens. Furthermore, virus isola-
tion was most successful during the first 2 weeks of the ill-
ness and was generally negative after day 22 of illness, even
though virus was detectable in these specimens by RT-PCR. 
Discussion
In April 2003, the first-generation diagnostic tests for
the SARS-CoV became available to clinicians caring for
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Table 1. SARS-CoV RNA detection by RT-PCR in clinical 
specimens
a 
Category 
Patients 
tested 
Patients  
positive (%) 
Clinical     
Clinical SARS (n = 590)  537  322 (60.0) 
Suspected SARS (n = 79)  70  1 (1.4) 
Non-SARS febrile respiratory 
illnesses (n = 379)  341  2 (0.6) 
Hospital controls     
Cohort 1: fecal samples from non-
SARS  patients with diarrhea  184  1 (0.5) 
Community controls      
Cohort 2: throat swabs from patients 
with nonrespiratory illness visiting 
community physicians.   148  0 (0.0) 
aSARS, severe acute respiratory syndrome; SARS-CoV, severe acute respiratory 
syndrome coronavirus; RT-PCR, reverse transcriptase–polymerase chain reaction. 
Table 2. Serologic response to SARS coronavirus
a 
Clinical category  No. of patients  Paired sera available for study 
No. (%) of patients with fourfold rise  
in antibody titer to SARS-CoV 
Clinical SARS  590  417  384 (92.1) 
Suspected SARS  79  11  1 (9.1) 
Not SARS  379  25  2 (8.0) 
Controls  45  45  0 (0.0) 
aSARS, severe acute respiratory syndrome; SARS-CoV, severe acute respiratory syndrome coronavirus. 
bAn additional 47 convalescent-phase sera were subsequently tested without any further evidence of antibody to SARS-CoV. patients in whom SARS was considered in the differential
diagnosis. Normally, new laboratory diagnostic tests are
extensively evaluated and validated before they are intro-
duced in routine clinical practice. However, in the case of
SARS, a new and poorly understood disease, these first-
generation test results were provided to clinicians on the
understanding that the tests had not been validated and
results had to be interpreted with caution. 
Continued improvement of the sensitivity of RT-PCR
methods (12) makes an analysis of the sensitivity of these
first-generation diagnostic methods less relevant.
However, these results provide useful information on the
best specimens for detection of virus at different stages of
illness, the tissue tropism of the virus, and the duration of
virus excretion. 
Culture of SARS-CoV for preparing the virus-infected
cell smears and for virus isolation was carried out under
BSL3 conditions, but routine clinical specimens were
processed in the clinical virology laboratory under BSL2
conditions after enhanced and reinforced education on
safety and good laboratory practice. Given that up to 250
specimens per day were being processed for RT-PCR
detection and serologic testing during peak periods, the
workload could not be managed in a BSL3 laboratory.
None of the laboratory staff became ill with SARS symp-
toms, indicating that clinical specimens for serologic test-
ing and RT-PCR can be processed safely in BSL2 level
conditions.
The association of SARS-CoV with the clinical syn-
drome of SARS is illustrated by the detection rates of viral
RNA in clinical specimens (60% in patients with SARS,
0.6% in the non-SARS group, and 0.3% of controls). Viral
RNA detection by these first-generation RT-PCR tests is
less sensitive than serologic testing for diagnosing SARS.
Correspondingly, 92% of 417 patients with clinically diag-
nosed SARS and none of the paired sera from 45 unrelat-
ed controls seroconverted to SARS-CoV. However, 2 of 25
patients designated as “not SARS” category from whom
paired sera were available also seroconverted. Paired sera
were available from only a few (25 of 379) patients in the
“not SARS” group. At a time of intense pressure on the
clinical front-line staff, there was little incentive to obtain
convalescent-phase sera from patients believed not to have
SARS. These 25 patients may represent a biased sample of
the larger group of non-SARS patients. This contention is
supported by the fact that a further 47 convalescent-phase
sera subsequently obtained from this group of “not SARS”
patients failed to show any additional antibodies to SARS.
Even patients in the “not SARS” category had a febrile,
respiratory, often pneumonic, illness; one of the two
patients in the “not SARS” category who had evidence of
seroconversion had an undiagnosed pneumonic illness,
while the other had an undiagnosed febrile illness without
radiologic consolidation of the lung. Overall, a clinical
diagnosis of SARS is closely correlated with detection of
viral RNA by RT-PCR and seroconversion supporting the
etiologic association of SARS-CoV and SARS. 
None of 2,400 blood donor sera collected in Hong
Kong during the height of the SARS outbreak has any evi-
dence of antibody to the virus. This finding suggests that
the spread of SARS-CoV infection in the general commu-
nity was minimal, with most of the infection associated
with clusters and hospital outbreaks (13). 
The RT-PCR detection rates for SARS-CoV in respira-
tory, stool, and urine specimens in the 383 patients with
seroconversion to SARS-CoV show that viral shedding
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Figure. Reverse transcriptase–polymerase chain reaction percent
positive in nasopharyngeal aspirates, nose and throat swabs, and
stool and urine specimens at different days after onset of illness in
patients with serologically confirmed severe acute respiratory syn-
drome. NPA, nasopharyngeal aspirate; NS/TS, nasal and throat
swabs.
Table 3. SARS coronavirus RNA detection in saliva, endotracheal aspirates, and sputum at different times after onset of illness in 
patients with serologically confirmed SARS-CoV infection
a 
D after onset  Positive saliva samples/total (%)  Positive endotracheal aspirate/total (%)  Positive sputum/total 
0–4  ND  ND  3/6 
5–10  1/6 (17.0)  1/2  3/3 
11–20  6/45 (13.3)  2/3  1/1 
21–30  2/96 (2.1)  13/19 (68.4)  ND 
31–40  3/58 (5.2)  1/1  ND 
41–50  1/29 (3.4)  ND  ND 
>50  0/40 (0.0)  0/1  0/1 
aSARS, severe acute respiratory syndrome; SARS-CoV, severe acute respiratory syndrome coronavirus; ND, not done. 
%progressively increased from onset of the illness until
approximately day 11 after onset. Since the first-genera-
tion RT-PCR test has relatively low sensitivity, these
results reflect the increasing viral load at different clinical
sites during the illness. Whereas these data are cross-sec-
tional, in a previous study viral load in nasopharyngeal
aspirates was followed up longitudinally in nasopharyn-
geal specimens collected at days 5, 10, and 15 after illness
onset; results of this study also indicated that viral load
peaks at day 10 of illness (4). Such a profile of a progres-
sive increase in viral load is unusual for respiratory viral
infections. Most other infections (e.g., respiratory syncy-
tial virus, influenza) have peak viral titers in the respirato-
ry secretions at or soon after the onset of clinical illness,
after which viral titers and laboratory diagnostic yield
decrease progressively (14). This “crescendo” pattern in
SARS-CoV detection rates and viral load in clinical spec-
imens has a number of implications. The pattern explains
the poor sensitivity of the first-generation diagnostic tests
during the first 5 days of the illness and emphasizes the
challenge in making laboratory diagnosis early in the
disease. These results may also suggest a fundamental dif-
ference in the efficacy of the innate immune response in
controlling SARS-CoV infection, in contrast, for example,
with influenza infection. Innate immune mechanisms are
the earliest host defenses that control viral replication and,
in the case of many respiratory viruses, do so within the
first few days of illness, even before the specific adaptive
immune responses have been activated. This response does
not appear to occur with SARS, and viral load in the respi-
ratory tract (4) begins to fall only when the antibody
response appears, i.e., at approximately day 10 after onset
of illness (4,5). This finding may suggest that SARS-CoV
is able to evade the host innate response and requires the
adaptive immune response to bring the infection under
control. Finally, the peak viral load in the 2nd week of ill-
ness would predict that virus is more likely to be transmit-
ted later in the course of the illness. This result indeed
accords with epidemiologic observations (15). With regard
to observations of viral load, the frequent use of steroid
therapy in hospitals (16) is a confounding factor that may
contribute to the increase in virus load later in the illness.  
The relative virus detection rates from different speci-
mens during the illness suggests that respiratory specimens
(nasopharyngeal aspirate, throat swab) are more useful in
the first 4 days of the illness, while fecal samples are bet-
ter later in the illness. Urine samples, on the other hand, are
not useful at any stage of the illness. Aproductive cough is
not common in the early stage of illness, but in patients
who do produce sputum, this specimen provides a high
diagnostic yield. Thus, nasopharyngeal aspirates, throat
swabs, and sputum, if available, are the best specimens in
the first 5 days of the illness.  
Detecting virus in the fecal and urine samples, in addi-
tion to the respiratory tract, suggests that SARS is not
restricted to the respiratory tract. The finding of diarrhea
unrelated to antimicrobial drug use in a number of patients
supports evidence that the disease is not a purely respirato-
ry one (4). A number of animal coronaviruses (e.g., mouse
hepatitis virus and feline coronavirus) have tropism for
multiple organs (17). Viral shedding is detectable by RT-
PCR in the respiratory, gastrointestinal, and urinary tracts
for many weeks after onset of illness, reflecting continued
virus replication at these sites. However, SARS-CoV can-
not be readily cultured from any of these sites after week 3
of illness. The viral RNA detected by RT-PCR after week
3 of illness is unlikely to represent persistence of viral
RNA in the absence of ongoing viral replication. The
apparent dissociation between virus isolation and RT-PCR
may reflect the mucosal antibody’s neutralizing the virus
and rendering it less infectious. This observation also
accords with the apparent absence of transmission of infec-
tion after week 2 of illness. The fact that virus isolation
was done retrospectively may have affected the overall
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Table 4. RT-PCR for diagnosis of SARS-CoV in the first 5 days 
of illness in patients with serologically confirmed SARS-CoV 
infection
a 
Specimens evaluated  Positive/tested (%) 
Nasopharyngeal aspirate  29/98 (29.6) 
Swabs (throat, nose)    15/53 (28.3) 
Sputum  5/9 (55.6) 
Stool  5/25 (20.0) 
Urine  0/15 (0.0) 
aSARS, severe acute respiratory syndrome; SARS-CoV, severe acute respiratory 
syndrome coronavirus; RT-PCR, reverse transcriptase–polymerase chain reaction. 
Table 5. Virus isolation from specimens positive for SARS-CoV by RT-PCR
a  
Sample type 
Wk  Positive NPA/sputum/total (%)  Positive TS/total (%)  Positive stool/total (%)  Positive urine/total (%)  Total pos/total tested (%) 
1  3/11 (27.3)  0/3 (0)  0/0 (0)  0/0 (0)  3/14 (21.4) 
2  20/37 (54.1)  1/6 (16.7)  0/11 (0)  1/4 (25.0)  22/58 (37.9) 
3  0/6 (0)  1/6 (16.7)  1/18 (5.6)  0/0 (0)  2/30 (6.7) 
4  0/3 (0)  0/0 (0)  0/7 (0)  0/0 (0)  0/10 (0) 
Total  23/57 (40.4)  2/15 (13.3)  1/26 (3.8)  1/4 (25.0)  27/112 (24.1) 
aSARS, severe acute respiratory syndrome; SARS-CoV, severe acute respiratory syndrome coronavirus; RT-PCR, reverse transcriptase–polymerase chain reaction; NPA, 
nasopharyngeal aspirate; TS, throat swab. 
 isolation rate. However, SARS-CoV appears relatively sta-
ble to freezing and thawing and is stable for many weeks
in clinical specimens at 4°C or frozen at –70°C (K.H. Chan
and J.S.M. Peiris, unpub. data). In any event, such a bias
would be expected to be uniform both early and late in the
disease.
In summary, SARS is closely associated epidemiologi-
cally with the novel SARS-CoV. The unusual profile of
viral shedding from the respiratory tract may explain some
of the observed transmission pattern of this disease,
including the predilection for affecting healthcare workers. 
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